ÜA ve hemogram değerlerinin onkoloji hastalarında sürvi ve mortalite açısından bir ilişkisinin olup olmamasını saptamak amacıyla yaptığımız çalışmayı şu şekilde özetleyebiliriz:
1) 997 hastayı çalışmamıza dahil ettik. Hastaların 553 (%55)’ü kadın, 444 (%45)’ü erkekdi. 01.08.2015 itibariyle, 628 hastanın(%63) ise yaşadığı saptandı.
2) 428 hastanın ÜA değerlerine (%43), 567 hastanın (%57) ise hemogram, üre ve kreatinin değerlerine ulaşıldı.
3) Ortalama ÜA değerleri tüm hastalar için 4,79 (± 1,82) mg/dl, yaşayan hastaların (260 kişi,%65) 4,57 (± 1,53) mg/dl, ölen hastaların ise (140 kişi,%35) 5,20 (± 2,22) idi.
4) Yaşayan ve ölen 2 grup karşılaştırıldığında; ölen hasta grubunda üre, kreatinin, ÜA, PMNL, Nötrofil%, Monosit%, Nötrofil, Monosit, Nötrofil/Lenfosit oranındaki yüksekliğin ve Hematokrit,Lenfosit ve Lenfosit% sindeki düşüklüğün anlamlı olduğu saptandı.
5) ÜA’i yüksek hastalarla ÜA’i normal ve düşük olan hastalar karşılaştırıldığında; ÜA’i yüksek olan grupta Üre, Kreatinin, ÜA, Eritrosit ve Hematokrit değerlerinin anlamlı olarak yüksek olduğu görüldü.
6) Sağkalım sürelerine bakıldığında en düşük sağkalımın düşük ÜA’i olan grupda olduğu (18,201 ± 1,426) , yüksek grupda (20,571 ± 2,779) olduğu ve en yüksek sağkalımın normal grupta (70,962 ± 10,244) olduğu görüldü.
7) Her 3 grubu karşılaştırdığımızda normal grubun sağkalım sürelerinin düşük gruba göre anlamlı olarak yüksek olduğu (p: 0,030), normal grubun sağkalım sürelerinin yüksek gruba göre anlamlı olarak daha yüksek olduğu bulundu
39 (p:<0,001). Düşük grupla yüksek grup karşılaştırıldığında sağkalım süresi açısından bir anlam olmadığı saptandı.
8) Düşük ve normal ÜA seviyelerine sahip hastaları beraber değerlendirip (1.grup), yüksek ÜA seviyelerine sahip hastalarla karşılaştırdığımızda (2.grup) ilk grupdaki hastaların sağkalım sürelerinin anlamlı olarak daha yüksek olduğu saptandı.
9) Değişken parametreleri değerlendirdiğimizde ÜA (p:0,001), normalden yüksek ÜA değerlerinde, Kreatinin ,Üre , PMNL, Nötrofil, Monosit ,Tanı yaşı, Nötrofil%, Monosit%, Bazofil% ve Nötrofil/Lenfosit oranlarındaki birim artışların; Lenfosit, Lenfosit%, Hemoglobin ve Hematokrit deki birim azalmaların ise mortaliteyi arttırdığı görülmüştür. Bunun yanında erkek cinsiyetin de tek başına mortaliteyi bağımsız olarak arttırdığı saptanmıştır. 10) Yapılan analizlerde ÜA’in yaştan, cinsiyetten ve nötrofil/lenfosit oranından
bağımsız bir mortalite öngörücüsü olduğunu; benzer şekilde Nötrofil/Lenfosit oranının yüksek olması da yaş ve cinsiyetten bağımsız şekilde mortalite öngörücüsü olduğunu gösterdi.
40 6. KAYNAKLAR
1. GLOBOCAN 2008, developed by the International Agency for Research on Cancer (IARC)
2. T.C Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, TÜRKİYE KANSER İSTATİSTİKLERİ
3. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda). 2005 Apr; 20: 125-33. ]
4. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 86,1989 : 9412–16
5. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol E 1992, vol 34: 78–84. ]
6. So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010 Jun 1; 120 (6) : 1791-9.
7. Ascherio A, et al. Arch Neurol 2009; 66: 1460–68.
8. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda). 2005 Apr; 20: 125-33.]
9. Hille R: Molybdenum-containing hydroxylases. Arch Biochem Biophys 2005, 433 (1): 107–16.
10. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-51. 11. Volk KJ, Lee MS, Yost RA, and Brajter-Toth A. Electrochemistry/ thermospray/tandem mass spectrometry in the study of biooxidation of purines. 1988 Anal Chem 60: 720–22
41 12. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA,Schuler G, Coats AJ, Anker SD, and Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo- controlled studies. Circulation 2002, 105: 2619–24.
13. Champe P.C, Harvey Urate Transport. Kidney İnt 1996 ; 49 : 1549-51. 14. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008 Jan; 324 (1): 1-7
15. Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 8, 1965: 694–706.
16. Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, et al: SLC2A9 is a highcapacity urate transporter in humans. PLoS Med 2008, 5(10): e197.
17. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, et al: Plasma urate level is directly regulated by avoltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008, 283 (40): 26834–38.
18. Acworth IN, Bailey B. Reactive Oxygen Species. In: The handbook of oxidative metabolism. Massachusetts: ESA Inc., 1997, p. 1-1 to 4-4
19. Reiter RJ. Oxidative processes and antioxidant defense mechanisms in the aging brain. FASEB J, 1995; 9: 526-33.
20. http://www.mustafaaltinisik.org.uk/21-adsem-01.pdf
21. Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78, 1981: 6858–62.
42 22. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 14, 1993: 615–631.
23. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376: 333– 7.
24. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid.Biochem J. 1986; 235 (3): 747–54.
25. Whiteman M, Ketsawatsakul U, Halliwell B. A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci. 2002; 962: 242–59.
26. Muraoka S, Miura T. Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol. 2003; 93 (6): 284–89.
27. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid inthe presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase.Biochem Pharmacol. 2005; 70 (3): 343– 54.
28. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copperinduced low- density lipoprotein oxidation: a study using uric acid. Biochem J. 1999; 340(pt 1):143–52
29. Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid.J Lipid Res. 2003; 44 (3): 512–21.
30. Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999; 372 (2): 285–94.
43 31. Cook S, Hugli O, Egli M, Ménard B, Thalmann S, Sartori C, Perrin C, Nicod P, Thorens B, Vollenweider P, Scherrer U, Burcelin R. Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. Diabetes. 2004;53 (8): 2067–72.
32. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly. 2003; 133 (25–26): 360–63.
33. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance, hyperlipidemia and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104 (3): 342–45
34. Suzuki T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide. 2007; 16 (2): 266–73.
35. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008; 27 (8): 967-78.
36. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67 (5),2005 : 1739–42.
37. Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol CellPhysiol. 2008; 295 (5): C1183–90.
38. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress.Am J Physiol Cell Physiol. 2007; 293 (2): C584–96.
39. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444 (7121):860–67.
44 40.Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh- Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen- activated protein kinase and cyclooxygenase-2. Hypertension.2003; 41 (6) :1287–93 41. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR,Ballantyne CM. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301–07.
42. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005; 25 (1): 39–42.
43. Reaven GM: Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 44,1993 :121–31.
44. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Available at: http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf. Accessed June 4, 2006.
45. National Cholesterol Education Program: Third report of the National Cholesterol Education Program (NCEP) on Detection and Treatment of High Blood Cholesterol inAdults (Adult Treatment Panel III) final report. Circulation 106, 2002: 3143–21.
46. Alberti KGM, Zimmet P, Shaw J: Metabolic syndrome: Anew world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23, 2006: 469–80.
47. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA,Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156, 2002:1070 –77.
45 48. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, Zaccaro D, Bergman RN, Savage PJ, Haffner SM:Insulin resistance and hypertension. Hypertension 43, 2004: 1324–31.
49. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. DiabetesCare 24, 2001: 683–89.
50. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2002 : 2709–16
51.Chen J, Muntner P, Hamm LL, Jones DW, Batuman V,Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140, 2004 :167–74
52.Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML,McClellan WM: Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 13, 2002 : 1626–1634
53.Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS:Body mass index and risk for end-stage renal disease. AnnIntern Med 144, 2006 : 21–28
54.Agnani S, Vachharajani VT, Gupta R, Atray NK, Vachharajani TJ: Does treating obesity stabilize chronic kidney disease? BMC Nephrol 6, 2005 : 7
55.Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U,Ori Y: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14, 2003 : 1480 –86
56.Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM:Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 324, 2002: 127– 37
46 57.Wisse BE: The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity.J Am Soc Nephrol 15, 2004 : 2792–800
58.Sun L, Halaihel N, Zhang W, Rogers T, Levi M: Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277, 2002 : 18919–27
59.Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24, 2001 : 691–97
60.Segura J, Campo C, Ruilope LM: How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens 4, 2002: 332– 36
61.Tseng CH: Correlation of uric acid and urinary albümin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 68, 2005: 796–801
62.Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M:Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 87, 2001 : 333–39
63.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH,Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 2001 : 1101–06
64.Nakagawa T, Mazzali M, Kang D-H, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23, 2003 : 2–7
65.Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces severe cortical vasoconstriction and perpetuates glomerular hypertension in normal rats and in experimental chronic renal failure.Kidney Int 67, 2005 : 237–47
47 66.Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C,Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ:Hyperuricemia induces endothelial dysfunction. Kidney Int 67, 2005 : 1739–42
67.Kang D-H, Park SK, Lee IK, Johnson RJ: Uric acid induced C-reactive protein (CRP) expression: Implication on cell proliferation and nitric oxide production in human vascular cells. J Am Soc Nephrol 16,2005 : 3553–62
68.Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA,Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol RenalPhysiol 290, 2006 : 625–31
69.Hallfrisch J: Metabolic effects of dietary fructose. FASEB J 4 1990 : 2652–60 70.Memişoğulları R, Taysi S, Bakan E, Çapoğlu İ. (2003) Antioxidant status and lipid peroxidation in type II diabetes mellitus.Cell Biochem Funct. 21: 291–96.
71.Memişoğulları R. (2005) Diyabette Serbest Radikallerin Rolü ve Antioksidanların Etkisi. Düzce Tıp Fakültesi Dergisi 3: 30-9.
72.American Diabetes Association. National diabetes fact sheet.2002. http://www.diabetes.org/diabetes-statistics.jsp
73.Shichiri M, Iwamoto H, Shiigai T. Diabetic renal hypouricemia.Arch Intern Med 1987; 147: 225-28
74.Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H.Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127: 321-36
75.Andrade JA, Kang HC, Greffin S, Garcia Rosa ML, Lugon JR. Serum uric acid and disorders of glucose metabolism:the role of glycosuria. Braz J Med Biol Res 2014; 0: 0
48 76.Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 2001; 31: 318-21
77.Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy.Diabet Med 1998; 15: 508-14
78.Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. JDiabetes Complications 2014; 28: 124-29
79.Anan F, Masaki T, Ito Y, Eto T, Umeno Y, Eshima N, Saikawa T, Yoshimatsu H. Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients. Metabolism 2010; 59: 314-19
80.Lee JJ, Yang IH, Kuo HK, Chung MS, Chen YJ, Chen CH, Liu RT. Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan-A 3-year prospective study. Diabetes ResClin Pract 2014; Epub ahead of print
81.Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?:A systematic review and meta- analysis based on observational cohort studies. BMC Nephrol 2014; 15: 122
82.Nan H, Dong Y, Gao W, Tuomilehto J, Qiao Q (2007) Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract. 76: 68–74.
83.Hayden MR, Tyagi SC. (2004) Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab. 1: 1-10.
84.Torun M, Yardim S, Simsek B, Burgaz S. Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther. 1998 Feb;23 (1): 25-9.
49 85.Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis2000; 148: 131–9.
86.Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. (2005) Hyperuricemia induces endothelial dysfunction.Kidney Int. 67: 1739–42.
87.Waring WS, Webb DJ, Maxwell SR.Uric acid as a risk factor for cardiovascular disease. QJM. 2000 Nov;93 (11): 707-13
88.Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem.1991; 266: 8604–08
89.Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology.
90.Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-67
91.Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery.Am Heart J 1991; 121: 20-24
92.Gelber AC, Klag MJ, Mead LA, Thomas J, Thomas DJ, Pearson TA, Hochberg MC.Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med. 1997; 157: 1436–40.
93.Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole- Wilson PA, Coats AJ. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998; 19: 1814–22.
94.Thomas RD, Newill A, Morgan DB. The cause of the raised plasma urea of acute heart failure. Postgrad Med J. 1979; 55: 10–14.
50 95.Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999; 13: 682–85.
96.Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Pérez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006; 12: 491-98
97. Bjorge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, Stocks T, Selmer R, Nagel G, Almquist M, et al: Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010, 19 (7): 1737–45.
98. Vona-Davis L, Howard-McNatt M, Rose DP: Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007, 8 (5): 395–408.
99. Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, De Marco M, Cavalcanti E, D'Aiuto M, Fucito A, et al: Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther 2011, 10 (12): 1240–43.
100. Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A, Negri E, La Vecchia C: Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011.
101. Porto LA, Lora KJ, Soares JC, Costa LO: Metabolic syndrome is an independent risk factor for breast cancer. Arch Gynecol Obstet 2011, 284 (5): 1271– 76.
102. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM, Stefanick ML, et al: A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18 (7): 2046–53.
103. Elias AD: Triple-Negative Breast Cancer: A Short Review. Am J Clin Oncol 2010, 33 (6): 637–45.
51 104. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triple- negative breast cancer–current status and future directions. Ann Oncol 2009, 20 (12): 1913–27.
105. Boffetta P, Nordenvall C, Nyren O, Ye W: A prospective study of gout and cancer. Eur J Cancer Prev 2009, 18 (2): 127–32.
106. Loh WJ, North BV, Johnston DG, Godsland IF: Insulin resistance-related biomarker clustering and subclinical inflammation as predictors of cancer mortality during 21.5 years of follow-up. Cancer Causes Control 2010, 21 (5): 709–18.
107. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112 (17): 2735–52.
108. Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annual review of medicine 2005, 56: 45–62.
109. Khunti K, Davies M: Metabolic syndrome. Bmj 2005, 331 (7526): 1153 54.
110. Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010, 6 (1): 30–38.
111. Ghaemi-Oskouie F, Shi Y: The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011, 13 (2): 160–66.
112. Martinon F: Update on biology: uric acid and the activation of immune and inflammatory cells. Curr Rheumatol Rep 2010, 12 (2): 135-41.
113. Martinon F: Detection of immune danger signals by NALP3. J Leukoc Biol 2008, 83 (3): 507–11.
114. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, et al: Uric acid stimulates monocyte
52 chemoattractant protein-1 production in vascular smooth muscle cells via mitogen- activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41 (6): 1287–93.
115. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16 (12): 3553–62.
116. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007, 293 (2): C584–96.
117. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt- sensitivity. Hypertens 2002, 40 (3): 355–60.
118. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26 (2): 269–75.
119. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH: Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010, 28 (6): 1234–42.
120. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5 (8): 1388–93.
121. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY: Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011, 60 (4): 1258–69.
122. Simao AN, Lozovoy MA, Simao TN, Morimoto HK, Dichi I: Adiponectinemia is associated with uricemia but not with proinflammatory status in
53 women with metabolic syndrome. J Nutr Metab 2012, 418094:418094.
123. Becker S, Dossus L, Kaaks R: Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009, 115(2):86–